Stephen J. DiPalma - 17 May 2021 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
Interim CFO
Signature
/s/ Damon Banks, as attorney-in-fact for Stephen DiPalma
Issuer symbol
INZY
Transactions as of
17 May 2021
Net transactions value
$0
Form type
4
Filing time
18 May 2021, 16:18:59 UTC
Next filing
24 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INZY Stock option (Right to Buy) Award $0 +15,000 $0.000000 15,000 17 May 2021 Common Stock 15,000 $15.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on May 17, 2021 and will vest as to 50% of the shares underlying the option on the date that is 180 days following the grant date and as to the remaining 50% of the shares underlying the option on the first anniversary of the grant date, provided Mr. DiPalma is providing services to the Company on such dates.